Hexamethylmelamine_chemotherapy_for_persistent_or_recurrent_epithelial_ovarian_cancer._The_purpose_of_this_study_was_to_determine_the_activity_and_toxicity_of_hexamethylmelamine_chemotherapy_in_patients_with_persistent_or_recurrent_epithelial_ovarian_cancer._Forty-nine_women_received_hexamethylmelamine_100_to_150_mg/day_for_14_days,_repeated_at_4-week_intervals._All_patients_had_previously_received_at_least_one_chemotherapy_regimen,_and_46_(94%)_had_received_cisplatin._Among_25_patients_with_clinically_measurable_disease_there_were_three_complete_and_two_partial_responses,_for_an_objective_response_rate_of_20%._The_mean_progression-free_interval_for_responders_was_38.6_months_versus_9.6_months_for_nonresponders_or_patients_with_nonmeasurable_disease_(p_less_than_0.001)._Thirteen_patients_are_alive,_eight_with_no_clinical_evidence_for_disease._Only_four_patients_discontinued_therapy_because_of_toxic_reactions._Hexamethylmelamine_appears_to_be_a_well-tolerated_drug_with_activity_against_ovarian_cancer_previously_treated_with_cisplatin.